Absci Corp 4

Somaratne Ransi Mudalinayake, CMO and Head of R&D of Absci Corp (ABSI), received two stock option awards totaling 1,033,000 shares of Common Stock on 2026-03-03.

On 2026-03-03, Absci Corp’s CMO and Head of R&D, Somaratne Ransi Mudalinayake, received two stock option awards covering a total of 1,033,000 shares of Common Stock. The first grant was an option to purchase 650,000 shares at an exercise price of $2.57 per share, expiring on 2036-03-02, and the second grant was an option to purchase 383,000 shares at an exercise price of $7.93 per share, expiring on 2036-08-02. Both option grants are service-based and vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in approximately equal monthly installments over the subsequent 36 months, contingent on the insider’s continued service. Assuming the Form 4’s reported post-transaction direct ownership refers to underlying common stock associated with these option awards, Mudalinayake beneficially owns 1,033,000 shares following these awards, representing a material equity-based compensation package but no open-market purchase or sale of shares.

Filing Facts

CIK

1672688

Ticker

ABSI

Form

4

Source Type

fda

Accession

0001672688-26-000129

Alert Tier

6